A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PDC 1421 (Primary)
- Indications Attention-deficit hyperactivity disorder; Major depressive disorder
- Focus Adverse reactions
- Sponsors BioLite Inc
- 21 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2013 New trial record